Expensive Treatment for Marginal Gain

Resist answering yes or no straight away — the station is about how the decision is made. In a system funded from a fixed budget, every pound spent on one treatment is a pound not spent on another, so the question is not "is four months of life valuable?" (obviously it is) but "is this the most health this money can buy?" That is the pillar of justice, and it is what makes the answer uncomfortable rather than obvious.

Show you know the machinery. Appraisal in the UK works through cost-effectiveness: the gain is expressed in quality-adjusted life years, which combine how long a treatment extends life with how good that life is, and it is weighed against a cost-per-QALY threshold. There are modifiers for end-of-life treatments and separate arrangements for promising cancer drugs still gathering evidence, plus the option of confidential price agreements with the manufacturer — which is often where a "no" turns into a "yes at a lower price".

Then argue both sides honestly. Against funding: the opportunity cost is real and is paid by patients you will never meet, and a high price for a marginal gain sets a precedent for the next drug. For funding: an average of four months conceals wide variation, with some patients gaining far more; quality of those months matters as much as their number; and a system that never funds marginal gains removes the incentive to develop treatments in hard diseases.

Land somewhere. Examiners mark the reasoning, not the verdict, but a candidate who refuses to commit after building the argument scores worse than one who concludes — for example, that it should be funded only if the price brings it within threshold or through a managed-access arrangement that collects the evidence.